Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT links. Here are some additional boards that can be a good resource for questions about stock valuation or for swing trade ideas. (no affiliation)
Value Microcaps Motherboard
http://investorshub.advfn.com/boards/board.aspx?board_id=3251
Value Microcaps Junior Miners
http://investorshub.advfn.com/boards/board.aspx?board_id=9329
~*~ Mining Mania ~*~
http://investorshub.advfn.com/boards/board.aspx?board_id=15977
Biotech Values
http://investorshub.advfn.com/boards/board.aspx?board_id=1418
$heff's $tation of $tocks & $olid DD
http://investorshub.advfn.com/boards/board.aspx?board_id=9413
2011-Rainmakers Island (RAIN
http://investorshub.advfn.com/2011-Rainmakers-Island-(RAIN)-11575/
thought ASEI would get ugly tried shorting early but no borrows so took it of L2 not to get caught long. needs to hold todays lows for you otherwise could see 46-48 quickly.
CHKR ouch. MAKO bounced nice but right back. you sell any? debated 23.45 short but passed. think all I did was short today lol at least 80% trades
well at least u are green...mesmerized by divi and riding some red on CHKR...little bounce at close helped..lets see tomoorow.
and ASEI ..avg down into 50's too..52 avg sucky but should bounce
mcds gift card for you lol jk
what a day. making money but feel like should be up 10-20k. between RENN/ARNA/LUX/ZNGA had at least 2-3 dozen trades where I took .01-.05 on 10k lots before .10-.40 moves
carefull i get royalties on whining,lol
got to finish taking my consolation prize. covered 1/2 11.5 still got 500 short left 11.97. sniff
I had everything set perfectly. just had to press the button. 1 sec brain fart and its gone.
More on T-HQ (THQI): FQ4 beats estimates on a 48% jump in total revenue. Net losses widened however as the maker of videogames and accessories continues to try to turn itself around following a disastrous dropoff in sales during the holiday shopping season. Shares =1.5% AH
yup...so hard to trade that spread so quickly
puke, would have been 3k in 3 sec
GLPW..GCOM...TRNS..PFMG..EML.. each show large trades 20%+ lower than close..weird
cool..saw those trades flash by..15 buyer cant be happy,lol
man missed the 15 short. edgx was 15 bid crossing 13.70 arca ask... trew me off. had I sent my 13.7 pretyped probably would have crossed him. ug. got 1k 11.97 short for kicks instead lol
OSUR pops bigly..15 a/h high..mosty near 12
An FDA advisory panel gives its unanimous approval to allow Orasure's (OSUR) HIV test kit to be sold in retail stores, enabling consumers to test for the virus at home. The mouth-swab test is already sold commercially to health-care professionals, and the projected benefits" of an in-home HIV test outweigh the "potential risks of false positive and false negative results." The FDA usually follows panel recommendations. Shares +3.3% AH.
seeking alpha blurb ..up before it opens,lol
prolly gap and hold,lol, at least until they do an offering,lmao...still just a panel yes..pdufa still uncertain..
http://www.businessweek.com/news/2012-05-11/orasure-hiv-test-has-risks-of-false-results-fda-says
they dumped it good last couple days ahead of good news. wonder how they play this. gap/rip or gap/fade.
NSU -10%..new 52 week low 2.80..miner
NUGT 7's..no luv..DUST reverse bounce candidate?
OSUR resumes 18:25 FDA approval
OraQuick(R) In-Home HIV Test Receives Unanimous Positive Recommendation From FDA Advisory Committee
GlobeNewswirePress Release: OraSure Technologies, Inc. – 4 minutes 16 seconds ago
Email
Print
Companies:
OraSure Technologies Inc.
RELATED QUOTES
Symbol Price Change
OSUR 9.10 0.00
Fantasy Finance
BETHLEHEM, Pa., May 15, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR - News) today announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) provided a unanimous positive recommendation for the Company's OraQuick(R) In-Home HIV Test. The BPAC provides advice to the FDA on issues related to the safety and effectiveness of biological products and medical devices seeking FDA approval.
The BPAC voted on two questions posed by FDA:
Do the projected benefits of the test outweigh the potential risks of false positive and false negative test results? The committee voted 17-0 in the affirmative to that question.
Do the available data provide reasonable assurance that the test is safe and effective for its intended use? The committee voted 17-0 in the affirmative to that question.
In addition to reviewing the Company's clinical data and performance, the BPAC considered data presented by the FDA and testimonies shared during the public comment session. The committee also discussed risk mitigation strategies that should be considered in addition to the current proposed labeling.
"We are pleased with the outcome of today's Blood Products Advisory Committee meeting," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "There was broad support expressed by the HIV community at today's meeting and we look forward to continuing our work with them in the fight against HIV. We believe the OraQuick(R) In-Home HIV Test will make a valuable contribution in this fight."
According to the Centers for Disease Control and Prevention, despite current testing options, there are approximately 1.2 million people in the U.S. that have HIV and approximately 240,000 of them are unaware of their status. Those who do not know they are HIV positive are unknowingly responsible for up to 70 percent of the 50,000 new HIV infections that occur each year.
Data presented at the BPAC included findings from the final phase of clinical testing. The Company also presented a benefit analysis, using recently published research on HIV transmission rates from persons living with HIV who are aware and unaware of their infection1. Assuming 1 million individuals tested with the OraQuick(R) In-Home HIV Test, the Company estimates that 9,087 HIV positive individuals would be identified with the added potential to prevent more than 700 onward transmissions annually. These would be in addition to those averted through current testing and intervention.
The OraQuick(R) In-Home HIV Test is an over-the-counter version of the OraQuick ADVANCE(R) Rapid HIV-1/2 Test which is currently sold into the professional market. The OraQuick ADVANCE(R) test is the first and only FDA-approved and CLIA-waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in oral fluid in 20 minutes. As the market leading rapid HIV test with close to 25 million tests sold, OraQuick ADVANCE(R) is used extensively throughout the United States in public health settings, hospitals, community-based organizations, and physician offices where HIV testing is conducted.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit www.orasure.com.
The OraSure Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6440
Important Information
This press release contains certain forward-looking statements, including with respect to products and potential regulatory approvals. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through an internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to obtain FDA approval of the OraQuick(R) HIV test for use in the over-the-counter market; ability to comply with applicable regulatory requirements; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts or minimum purchase requirements for the Company's products; impact of replacing distributors and success of direct sales efforts; inventory levels at distributors and other customers; ability to integrate and realize the full benefits of the Company's acquisition of DNA Genotek; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of the economic downturn, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance, extended shelf life or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical product components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to refinance outstanding debt under expiring credit facilities on acceptable terms or at all; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company's Securities and Exchange Commission filings, including its registration statements, Annual Report on Form 10-K for the year ended December 31, 2011, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
1 Hall HI, Holtgrave DR, Maulsby C., HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012 Apr 24;26(7):893-6.
Contact:
Investor Contact:
Ronald H. Spair
Chief Financial Officer
FREE has news involving YA Global (lol, the otc toxic finance champ)
Ahead of his successful campaign to get rid of Scott Thompson and win board seats, Dan Loeb boosted his stake in Yahoo (YHOO). Loeb's Third Point LLC held 70.5M Yahoo shares at the end of Q1, compared with 56M shares and 10M calls at the end of Q4. Third Point also established new positions in AAPL and GOOG, and liquidated its positions in SNDK and WFR.
guess that didn't help WFR,lol
COGO up a bunch a/h...580k trade @ 2.05 too
ECYT mid 6's..fade from pop to 8 a few weeks ago..interesting .. more interesting if tests 6..
yeah but the nfs on later short put me in the red with it.
David Einhorn's Greenlight Capital established new positions in Computer Sciences (CSCO) and Expedia (EXPE) in Q1. Assuming Einhorn maintained his position through April 27, the Expedia bet was a smart one. Einhorn also liquidated his positions in TRV,, FSLR, OVTI, and YHOO, and significantly cut his positions in MSFT, GM, and RIMM. EXPE +0.9% AH. (13-F)
(KITD): Q1 EPS of -$0.53 misses by $0.20. Revenue of $59M (+71% Y/Y) misses by $10M. Shares +1.9% AH
huge short on this..lets see what it does tommorrow
at least you got a little....
NCT off 5% on offering..high divi reit type thingy..did an offering in april too and seems to bounce..on watch
bi-polar market..so hard to know what will bounce for real and what will continue to step down into oblivion..market needs an enema...but a bounce first please...lol
had on watch list...got spooked on market tankage into close and didnt get a few lottos
SINA nice $4 spike on er. tried 55.4s short but got skunked
yes mfer bouncing huge lol
only bright side I kept trying to short from 27.2 but each time they'd cut me off so I'd cancel and it'd keep going higher. finally got some size filled near 29.4 nothing 29.0s fill me only 100 ask 29.2 then another 100 29.3 and another 100 29.36 lol lost some but.... MFER!! still looking for my 25.03 and 24.91 buys...
is that a ticker? lmao
Accretive Health Initiates Panel of Health Care Policy Experts to Establish National Standards for Health Care Providers' Financial Interactions with PatientsLast
update: 5/15/2012 3:33:00 PMOther Health Care Stakeholders Invited to Participate CHICAGO, May 15, 2012 (BUSINESS WIRE) --
Accretive Health, Inc. (AH) announced today that prominent health care and policy leaders have agreed to convene to develop a process for implementing national standards for how hospitals and other providers interact with patients regarding their financial obligations. This process will create first-of-kind national standards for understanding expected charges, available resources, counseling, billing and payment procedures regardless of the ability to pay. An independent accreditation process will accompany the new standards, providing patients with assurance that they will be treated compassionately and fairly. The group will identify and select an independent non-profit Standard Development Organization (SDO) to conduct a collaborative process among practitioners, patient advocates, and other interested parties. Once concluded, the group will advance the identified standards to a national accrediting organization. Accretive Health initiated this process in order to provide clarity and consistency among providers and, as a result, help ensure a more uniform and transparent experience for patients as hospitals work to become more financially stable and bring down the cost of care. The following noted health care and policy leaders have agreed to serve as independent conveners of the process: CHAIRMAN Michael O. Leavitt -- Former Secretary of U.S. Department of Health and Human Services, three-term governor of Utah and former administrator of the Environmental Protection Agency. He is currently the founder of Leavitt Partners, which specializes in the health care field, and has led numerous large public and private collaborations. ADVISORS Tom Daschle -- Former U.S. Senator from South Dakota, former U.S. Senate Majority Leader, served three terms in the U.S. House of Representatives and is a respected health care thought leader. He is currently a Distinguished Senior Fellow at the Center for American Progress and a member of the Health Policy and Management Executive Council at the Harvard School of Public Health. Bill Frist, M.D. -- Former U.S. Senator from Tennessee, former U.S. Senate Majority Leader, nationally recognized heart and lung transplant surgeon and health care thought leader. He was the 2010 Distinguished Professor of Business and Medicine at Vanderbilt University. Jamie Gorelick, J.D. -- Partner at the international law firm, WilmerHale, formerly served as U.S. Deputy Attorney General, General Counsel of the Department of Defense, Assistant to the Secretary of Energy, and as a member of the 9-11 Commission. She currently serves as co-chair of the American Bar Association Commission on Ethics. Mark B. McClellan, M.D., Ph.D -- Director, Engelberg Center for Health Care Reform, Senior Fellow at the Brookings Institution, former Administrator of the Center for Medicare and Medicaid Services (CMS) and former Commissioner of the Food and Drug Administration (FDA). He is a physician and economist. Donna E. Shalala, Ph.D -- President of the University of Miami and former Secretary of the U.S. Department of Health and Human Services, and accomplished scholar, teacher and administrator. She received the Presidential Medal of Freedom, the nation's highest civilian award, in 2008. Gov. Leavitt, who will lead the group, made the following statement about the collaboration and the need for standards: "Hospitals and doctors have a moral and legal obligation to treat patients medically in emergency situations and to do it in a compassionate and fair way. In doing so, medical providers face a dilemma. In order to assure hospitals remain financially viable and available to patients, they must assist these same patients in making financial arrangements for payment. Hospitals desire to do that in a sensitive and appropriate way, however, currently there are no clear standards to help guide their efforts. This collaboration is an effort to provide clear standards to help medical practitioners continuously improve -- while at the same time, providing patients with tools to help them know which hospitals and doctors follow the national standards." The selected SDO will convene relevant stakeholders from the health care industry -- including patient advocates, small and large health systems, privacy experts, physicians, insurers, Medicaid advocates, state Medicaid officials, trade organizations and others -- to evaluate current counseling, billing and payment practices. They will inventory existing standards, collect information on industry best practices, solicit public input, establish requirements for voluntary consensus standards and select a national accrediting body to certify the standards. Accretive Health and other interested organizations with responsibility to assure respectful and compassionate treatment of patients will be invited to participate. It is anticipated that the conveners will organize in May and commence their work in June. Because of the importance of this issue, Accretive Health, along with participating health care organizations, will provide financial resources for the creation of the group, which will act independently of any institution or health care organization in creating national standards for accreditation. Neither Accretive nor any of the health care organizations that provide support or input will play any role at all in the activities of the panel other than being interviewed by the independent Standards Development Organization to collect data. The participating organizations will have no insight into the panel's conclusions until they are final and announced. In a statement, Accretive Health CEO Mary Tolan invited others to join in the standards-setting process and expressed the Company's intent to earn full accreditation: "We believe strongly the industry will benefit from a thoughtful, independent, collaborative review and process, and we feel confident the industry will welcome this as a solution to a difficult, but critical challenge every patient and medical provider shares. We believe we have been a positive part of the process to date in our work for leading health care providers, helping thousands of formerly uninsured individuals get coverage for care. We hope this group becomes the gold standard for compassionate and fair patient interaction, reducing system errors and anxiety among patients about their cost of care, and making sure they are informed about coverage options regardless of their ability to pay." ABOUT ACCRETIVE HEALTH Accretive Health partners with healthcare providers to help them more effectively manage their revenue cycles, strengthen their financial stability, and improve the quality of care they provide while reducing overall healthcare costs. Our people, processes and sophisticated integrated technology complement our clients' existing resources to enhance results for patients, physicians and staff. For more information visit . SOURCE: Accretive Health, Inc. Accretive Health: Gary Rubin, 312-324-7813 or Leavitt Partners: Natalie Gochnour, 801-509-1198Copyright Business Wire 2012
yeah I though a million might be a lot, lol....
i saw that too had i not read the news i was more likely to play it
I saw they had insurance to cover potential profit losses, with a 1 million deductable....
crap i thought having their plant closed would send it lower
proves reading the news interfers with trading lol
the following was written by the founding moderator of this board,harbs
for me, the most profitable and consistent trades i make on a daily basis are the bounce trades...typically intra-day bounce plays..and the harder and longer they fall, the higher they bounce...
anything that is crashing down and belongs on watch belongs here...bb's, pinks, big board stocks - all of 'em...we run scans all day long - looking for those dropping at least 15-20%, or a stock that has been beaten down for days or weeks straight and finally turns up, a reversal of sorts..
ideally i'd like this to just be a thread where we can post a ticker during the day and not much more needs to be said...any bad news or anything causing the tank would be helpful, though...
this is not a long term thread, a break-out thread, an accumulation thread, a dd thread...let's nail the bottoms..
THIS IS FOR BOUNCES ONLY...(and reverse bounces - shorting)
the timid and faint of heart need not apply...
ps - i appreciate all of you that make your calls real time...as you can see, that is what i try and do ( sometimes i'll even post where my bid is, before i'm filled, or may never get filled )..bottom line is protect and build your own accounts, but if you have the time it's nice..( obviously, when you're flipping a naz 20 times in a day, it might not make a lot of sense to post all the trades )
and i appreciate the calls real-time because that helps people make money - it's not to say that anyone should buy or sell when i or you do, but heck, what good is it to tell us after the fact..how many times does a stock close up 1,000% and the supposed guru posts after hours -"oh, btw, i loaded the boat on xyz this am - made bank" hmmm, thanks..
ok, one other trade..when a stock shoots up like crazy, i like to call them "naz-crackers" lol..well we try and short those for the reverse bounce...day 1 of huge volume always scary to short into unless it's just an over done momo play...but days 2 and 3 are usually the best spot..
If you like bouncers check out our option board for quick gainers http://investorshub.advfn.com/boards/board.asp?board_id=12451
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |